Table of Contents Author Guidelines Submit a Manuscript
Computational and Mathematical Methods in Medicine
Volume 2018, Article ID 3719703, 11 pages
https://doi.org/10.1155/2018/3719703
Research Article

Quantitative Assessment of the Physiological Parameters Influencing QT Interval Response to Medication: Application of Computational Intelligence Tools

1Department of Pharmacoepidemiology and Pharmacoeconomics and Department of Social Pharmacy, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9 Street, 30-688 Kraków, Poland
2Simcyp (a Certara Company) Limited, Blades Enterprise Centre, John Street, Sheffield S2 4SU, UK
3Department of Pharmaceutical Technology and Biopharmaceutics, Jagiellonian University Medical College, Medyczna 9 St, 30-688 Kraków, Poland

Correspondence should be addressed to Jakub Szlęk; lp.ude.ju@kelzs.j

Received 20 September 2017; Accepted 3 December 2017; Published 4 January 2018

Academic Editor: David A. Winkler

Copyright © 2018 Sebastian Polak et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. M. Lester and J. Olbertz, “Early drug development: assessment of proarrhythmic risk and cardiovascular safety: the age of repolarization cardiac toxicity,” Expert Review of Clinical Pharmacology, vol. 9, no. 12, pp. 1611–1618, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. C. van Noord, M. Eijgelsheim, and B. H. C. Stricker, “Drug- and non-drug-associated QT interval prolongation,” British Journal of Clinical Pharmacology, vol. 70, no. 1, pp. 16–23, 2010. View at Publisher · View at Google Scholar · View at Scopus
  3. D. M. Roden, “Drug-induced prolongation of the QT interval,” The New England Journal of Medicine, vol. 350, no. 10, pp. 1013–1022, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. M.-L. Roy, R. Dumaine, and A. M. Brown, “HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine,” Circulation, vol. 94, no. 4, pp. 817–823, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. A. M. Brown, “hERG Block, QT Liability and Sudden Cardiac Death,” Novartis Foundation Symposia, vol. 266, pp. 118–131, 2005. View at Google Scholar
  6. K. S. Lee, “Ibutilide, a new compound with potent class III antiarrhythmic activity, activates a slow inward Na+ current in guinea pig ventricular cells,” The Journal of Pharmacology and Experimental Therapeutics, vol. 262, no. 1, pp. 99–108, 1992. View at Google Scholar · View at Scopus
  7. C. T. January and J. M. Riddle, “Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current,” Circulation Research, vol. 64, no. 5, pp. 977–990, 1989. View at Publisher · View at Google Scholar · View at Scopus
  8. B. Szabo, R. Sweidan, C. V. Rajagopalan, and R. Lazzara, “Role of Na+:Ca2+ exchange current in Cs+-induced early afterdepolarizations in Purkinje fibers,” Journal of Cardiovascular Electrophysiology, vol. 5, no. 11, pp. 933–944, 1994. View at Publisher · View at Google Scholar · View at Scopus
  9. D. M. Roden, R. Lazzara, M. Rosen, P. J. Schwartz, J. Towbin, and G. Michael Vincent, “Multiple mechanisms in the long-QT syndrome: current knowledge, gaps, and future directions,” Circulation, vol. 94, no. 8, pp. 1996–2012, 1996. View at Publisher · View at Google Scholar · View at Scopus
  10. P. K. Honig, D. C. Wortham, K. Zamani, D. P. Conner, J. C. Mullin, and L. R. Cantilena, “Terfenadine-ketoconazole interaction: pharmacokinetic and electrocardiographic consequences,” Journal of the American Medical Association, vol. 269, no. 12, pp. 1513–1518, 1993. View at Publisher · View at Google Scholar · View at Scopus
  11. P. K. Honig, R. L. Woosley, K. Zamani, D. P. Conner, and L. R. Cantilena, “Changes in the pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine with concomitant administration of erythromycin,” Clinical Pharmacology & Therapeutics, vol. 52, no. 3, pp. 231–238, 1992. View at Publisher · View at Google Scholar · View at Scopus
  12. P. K. Honig, D. C. Wortham, R. Hull, K. Zamani, J. E. Smith, and L. R. Cantilena, “Itraconazole affects single‐dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics,” The Journal of Clinical Pharmacology, vol. 33, no. 12, pp. 1201–1206, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. P. K. Honig, D. C. Wortham, K. Zamani, J. C. Mullin, D. P. Conner, and L. R. Cantilena, “The effect of fluconazole on the steady‐state pharmacokinetics and electrocardiographic pharmacodynamics of terfenadine in humans,” Clinical Pharmacology & Therapeutics, vol. 53, no. 6, pp. 630–636, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. P. K. Honig, D. C. Wortham, K. Zamani, and L. R. Cantilena, “Comparison of the effect of the macrolide antibiotics erythromycin, clarithromycin and azithromycin on terfenadine steady-state pharmacokinetics and electrocardiographic parameters,” Drug Investigation, vol. 7, no. 3, pp. 148–156, 1994. View at Publisher · View at Google Scholar · View at Scopus
  15. R. F. Bergstrom, M. J. Goldberg, B. J. Cerimele, and B. L. Hatcher, “Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine,” Clinical Pharmacology & Therapeutics, vol. 62, no. 6, pp. 643–651, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. D. E. Martin, B. D. Zussman, D. E. Everitt, L. J. Benincosa, R. C. Etheredge, and D. K. Jorkasky, “Paroxetine does not affect the cardiac safety and pharmacokinetics of terfenadine in healthy adult men,” Journal of Clinical Psychopharmacology, vol. 17, no. 6, pp. 451–459, 1997. View at Publisher · View at Google Scholar · View at Scopus
  17. K. H. W. J. ten Tusscher, D. Noble, P. J. Noble, and A. V. Panfilov, “A model for human ventricular tissue,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 286, no. 4, pp. H1573–H1589, 2004. View at Publisher · View at Google Scholar · View at Scopus
  18. B. Wiśniowska and S. Polak, “Virtual clinical trial toward polytherapy safety assessment: combination of physiologically based pharmacokinetic/pharmacodynamic-based modeling and simulation approach with drug-drug interactions involving terfenadine as an example,” Journal of Pharmaceutical Sciences, vol. 105, no. 11, pp. 3415–3424, 2016. View at Publisher · View at Google Scholar · View at Scopus
  19. B. Vandenberk, E. Vandael, T. Robyns et al., “Which QT correction formulae to use for QT monitoring?” Journal of the American Heart Association, vol. 5, no. 6, Article ID e003264, 2016. View at Publisher · View at Google Scholar · View at Scopus
  20. R Core Team, “R: A language and environment for statistical computing,” 2015, http://www.R-project.org/.
  21. J. Szlek, A. Pacławski, R. Llau, R. Jachowicz, and A. Mendyk, “Heuristic modeling of macromolecule release from PLGA microspheres,” International Journal of Nanomedicine, vol. 8, pp. 4601–4611, 2013. View at Publisher · View at Google Scholar · View at Scopus
  22. A. J. Cannon, “monmlp: Monotone multi-layer perceptron neural network,” 2017, http://cran.r-project.org/web/packages/monmlp/index.html.
  23. M. Kuhn, S. Weston, C. Keefer, and N. Coulter, “C code for Cubist by Ross Quinlan. Cubist: Rule- and Instance-Based Regression Modeling,” 2017, http://CRAN.R-project.org/package=Cubist.
  24. L. Breiman, “Random forests,” Machine Learning, vol. 45, no. 1, pp. 5–32, 2001. View at Google Scholar
  25. S. Milborrow, “Earth: Multivariate Adaptive Regression Splines,” 2017, http://cran.r-project.org/web/packages/earth/index.html.
  26. O. Flasch, O. Mersmann, T. Bartz-Beielstein, and J. Stork, “rgp: R genetic programming framework,” 2011, R package version 0.2-4, http://CRAN.R-project.org/package=rgp.
  27. J. Ypma, nloptr: R interface to NLopt, 2017, http://cran.r-project.org/web/packages/nloptr/index.html.
  28. B. Wiśniowska, A. Mendyk, J. Szlek, M. Kołaczkowski, and S. Polak, “Enhanced QSAR models for drug-triggered inhibition of the main cardiac ion currents,” Journal of Applied Toxicology, vol. 35, no. 9, pp. 1030–1039, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. J. Szlęk, A. Pacławski, R. Lau, R. Jachowicz, P. Kazemi, and A. Mendyk, “Empirical search for factors affecting mean particle size of PLGA microspheres containing macromolecular drugs,” Computer Methods and Programs in Biomedicine, vol. 134, pp. 137–147, 2016. View at Publisher · View at Google Scholar · View at Scopus
  30. J. R. Quinlan, “Learning with continuous classes,” in Proceedings of the 5th Australian Joint Conference on Artificial Intelligence, pp. 343–348, 1992.
  31. A. Liaw and M. Wiener, “Classification and regression by randomforest,” The R Journal, vol. 2, no. 3, pp. 18–22, 2002. View at Google Scholar
  32. J. H. Friedman, “Multivariate adaptive regression splines,” The Annals of Statistics, vol. 19, no. 1, pp. 1–67, 1991. View at Publisher · View at Google Scholar · View at MathSciNet
  33. W. Zhang and A. T. C. Goh, “Multivariate adaptive regression splines and neural network models for prediction of pile drivability,” Geoscience Frontiers, vol. 7, no. 1, pp. 45–52, 2016. View at Publisher · View at Google Scholar · View at Scopus
  34. J. R. Koza, Genetic Programming: On the Programming of Computers by Means of Natural Selection, MIT Press, Massachusetts, Mass, USA, 1992.
  35. “R scripts for multivariate analysis,” 2017, https://sourceforge.net/projects/rscriptsmultivariate/files/.